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Abstract: The effects of tyrosine on plasma response and cognition in aging are unknown. We assessed
the dose-dependent response to tyrosine administration in older adults in both plasma tyrosine
concentrations and working memory performance. In this double blind randomized cross-over
trial 17 older adults (aged 60–75 years) received a single administration of 100, 150, or 200 mg/kg
body weight of tyrosine. For comparison, 17 young adults (aged 18–35 years) received a dose of
150 mg/kg body weight of tyrosine. Tyrosine plasma concentrations were determined before and
90, 120, 150, 180, 210, and 240 min after tyrosine intake. Working memory was assessed using the
N-back task at 90 min after tyrosine administration. Older adults showed a dose-dependent increase
in plasma tyrosine concentrations (p < 0.001), and the plasma response was higher than for young
adults with the same dose (p < 0.001). Load-dependent working memory performance decreased with
higher doses of tyrosine (p = 0.048), especially in older adults with greater dose-dependent plasma
tyrosine responses (p = 0.035). Our results show an age-related increase in plasma tyrosine response,
which was associated with a dose-dependent decline in cognitive functioning in older adults.
Keywords: tyrosine; dose-response; aging; working memory; plasma amino acids;
catecholamines; dopamine
1. Introduction
Tyrosine is one of the conditionally essential amino acids and is particularly found in protein-rich
foods such as dairy, meat, fish, eggs, seeds, nuts, and beans. It can also be synthesized from the
essential amino acid phenylalanine, but this is dependent on sufficient availability of this precursor [1].
Studies of tyrosine supplementation in young adults showed that after doses of 100 mg/kg body
weight and 150 mg/kg body weight, peak plasma concentrations of the compound were reached
approximately two hours after ingestion. The increase in plasma tyrosine concentrations was more
pronounced and longer persisting after the 150 mg/kg body weight dose than after the 100 mg/kg body
weight dose [2]. With aging, changes in peripheral tyrosine absorption and metabolism, for example in
liver [3], muscles [4], and melanocytes [5], may occur and, consequently, the same dose of tyrosine may
lead to a different response in plasma (i.e., peripheral) tyrosine concentrations in older relative to young
Nutrients 2017, 9, 1279; doi:10.3390/nu9121279 www.mdpi.com/journal/nutrients
Nutrients 2017, 9, 1279 2 of 14
adults. We aimed to investigate this in older adults with three tyrosine doses using a randomized
cross-over design (100 mg/kg, 150 mg/kg, and 200 mg/kg body weight of tyrosine) and a 150 mg/kg
body weight dose of tyrosine in young adults for comparison.
Tyrosine is the precursor of the neuromodulatory catecholamines dopamine and noradrenaline [6,7].
In animal models, concentrations of brain tyrosine were shown to be modifiable by dietary intake [8]
and tyrosine administration enhanced central catecholamine synthesis in rodents [9–12] and in
humans [13]. Catecholamines, including dopamine, are important for working memory [14,15].
Several studies in young adults have shown that tyrosine administration can reverse working
memory impairments under stressful conditions (for reviews, see [16,17]), or increase cognition,
including working memory, in regular environmental conditions [18–20].
Aging is characterized by a decline in brain dopamine receptor and transporter binding [21],
which is accompanied by impairments in working memory [22–24]. Therefore, older adults may
also cognitively benefit from tyrosine supplementation, perhaps with increasing dose. Alternatively,
increasing tyrosine doses could potentially hamper cognition, as aging has also been shown to be
accompanied by (compensatory) up-regulation of dopamine synthesis capacity [25,26], which has
been related to, if anything, worse, rather than better, neurocognitive functioning relative to young
adults [25,27]. Moreover, it is unknown how age-related peripheral effects of tyrosine administration
would affect central (i.e., cognitive) functioning. Therefore, in addition to our primary aim into the
effects of tyrosine administration on plasma response, we explored the effects of the three tyrosine
doses on working memory performance in older adults and its relation to the plasma response. In the
absence of a placebo condition, we can only study dose-dependent effects of tyrosine administration.
Hence, our main secondary aim was to assess whether working memory performance would increase
or decrease with increasing tyrosine dose in older adults.
2. Materials and Methods
2.1. Participants
We included 17 young (17–35 years of age) and 17 older adults (60–75 years of age) with
a body mass index (BMI) between 18.5 and 27 kg/m2, who were Dutch-speaking and had a
normal or corrected-to-normal vision. Participants were recruited through an existing database of
volunteers with interest in participating in studies at Wageningen University. Exclusion criteria were:
(1) smoking; (2) thyroid problems; (3) use of tyrosine supplements or medication that can interfere with
tyrosine’s action; (4) following a low-protein diet as prescribed by a dietician or physician; (5) alcohol
consumption >14 (women) or >21 (men) units per week; (6) Mini-Mental State Examination (MMSE)
score <24 (only for older adults) [28]; (7) Intelligence Quotient (IQ) < 85 as estimated by the Dutch
version of the National Adult Reading Test (NART) [29]; (8) intestinal problems that affect nutrient
absorption; (9) Parkinson’s Disease, history of depression or other clinically-significant psychiatric
or neurological disorder; (10) under treatment for cardiac or vascular diseases and use of medication
for these conditions; (11) being allergic or having a dislike for the product carrier (banana-flavoured
yoghurt); (12) bad venous access as judged by the research nurse; and (13) general medical conditions
affecting test performance, such as repetitive strain injury (RSI) or sensorimotor handicaps, as judged
by the investigator. In addition, performance on the N-back task during the screening test session
(15 min-session without feedback) needed to be >60% on levels 0-, 1- and 2-back to assure participants
performed according to the instructions. If performance after two practice sessions with feedback and
a 15-min test session without feedback was <60%, participants performed one more practice session
with feedback and 15-min-session without feedback. If performance was still <60%, participants were
excluded. The performance score was calculated by hits/(hits + misses + incorrect rejections + false
alarms) × 100% for each level. The Wageningen University Medical Ethical Committee (METC-WU)
approved the study on 6 October 2014 (protocol number 14/20). Participants gave written informed
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consent and were compensated for participation. This trial was registered at www.trialregister.nl
as NTR4846.
2.2. Study Design
Participants were screened between October 2014 and November 2014, and intervention took
place between November and December 2014. A pre-screening comprising an initial check on eligibility
criteria was performed by phone. When potential participants fulfilled to the criteria, they were invited
for a screening visit during which they were informed about study details and signed the informed
consent after which possible inclusion based on in- and exclusion criteria (see Participants) was
further determined. Furthermore, participants were weighed and familiarized with the N-back task,
which was repeated during the test visits.
We used a double-blind, randomized, cross-over design to investigate the response in plasma
tyrosine concentrations following administration of a single dose of 100, 150, or 200 mg/kg body weight
of tyrosine to healthy older adults (Figure 1). There was at least one week between the different test
conditions (i.e., doses). A reference group of young adults received a dose of 150 mg/kg body weight
tyrosine. Test sessions took place in the morning after an overnight fast (10–12 h). An independent
researcher randomized the older adults over the three different doses of tyrosine by means of six
computer-generated counterbalanced orders.
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day on which they received a dose of 150 mg/kg body weight of tyrosine. The timeline below 
represents a test day in minutes. Black arrows: time points of blood collection for plasma tyrosine 
concentrations, green arrow: time point of tyrosine supplementation, and orange arrows: time points 
of start of practicing (t = 15) and performance of N-back working memory task (t = 95). 
2.3. Tyrosine Supplementation 
The doses of L-tyrosine powder (Bulkpowders™, Sports Supplements Ltd. Colchester, Essex, 
United Kingdom) were mixed with banana-flavored yoghurt (Arla® Foods Nederland, Nijkerk, The 
Netherlands) in a 1:20 ratio to ensure comfortable ingestion of the product. Weighing of the doses 
and preparing and coding the samples were performed by a staff member not involved in the study. 
Participants had to consume the whole portion within 10 min, together with one glass of water (150 
mL). 
2.4. Sample Size Calculation 
Sample size calculation was based on plasma tyrosine concentration, the primary study 
parameter. We calculated the effect size of a comparable previous study that assessed plasma tyrosine 
concentrations in young adults after doses of 100 and 150 mg/kg body weight of tyrosine [2]. Given 
the post-hoc calculated effect size in this study (d = 0.88), the a priori sample size calculation for the 
current study indicated a sample of 13 participants, using an alpha of 0.05 and a beta of 0.8. Sample 
size for the secondary objective, i.e., differences in working memory performance for the three 
Fig re 1. St y design.
Older adults (n = 17) ingested 100, 150 or 200 mg/kg body weight of tyrosine on three test days in
a random order with one week in between. Young participants (n = 17) performed only one test day
on which they received a dose of 150 mg/kg body weight of tyrosine. The timeline below represents a
test day in minutes. Black arrows: time points of blood collection for plasma tyrosine concentrations,
green arrow: time point of tyrosine supplementation, and orange arrows: time points of start of
practicing (t = 15) and performance of N-back working memory task (t = 95).
2.3. Tyrosine Supplementation
The doses of L-tyrosine po der (Bulkpowders™, Sports Supplements Ltd. Colchester, Essex,
United Ki gdom) were mixed with banana-flavored yoghurt (Arla® Foods Nederland, Nijkerk,
The Netherla ds) in a 1:20 ratio to ensure comfortable ingestion of the product. Weig ing of the
doses and prep ring and coding the samples were perfor ed by a staff member not involved in the
study. Participants had to consume the whole portion within 10 min, together with one glass of water
(150 mL).
2.4. Sample Size Calculation
Sa ple size calculation was based on pl sma tyrosine concentr tion, the primary study
parameter. We calculated the effect size of a comparable previous study that assessed plasma tyrosine
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concentrations in young adults after doses of 100 and 150 mg/kg body weight of tyrosine [2]. Given the
post-hoc calculated effect size in this study (d = 0.88), the a priori sample size calculation for the current
study indicated a sample of 13 participants, using an alpha of 0.05 and a beta of 0.8. Sample size for
the secondary objective, i.e., differences in working memory performance for the three tyrosine doses
in older adults, was calculated based on the effect size of a study that tested the effect of tyrosine
supplementation on N-back performance in young adults [18]. Calculations with this effect size of
d = 0.7, resulted in a sample size of 17 participants. To have sufficient power for both the primary and
the secondary objective we included 17 participants per group.
2.5. Cognitive Performance: N-back Working Memory Task
Participants performed four conditions of a numerical (digits 0–9) N-back task on the computer
(previously described in [30,31] (Figure 2)): a control condition, where a single digit is specified as the
target (0-back) and conditions with increasing cognitive load, where the target is any digit identical to
the digit presented n trials prior (1-back, 2-back, and 3-back). The digits were presented in white in the
center of a black screen using a blocked design with 32 blocks (eight blocks for each condition).
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Figure 2. Schematic overview of the numerical N-back task.
At the start of the task, and in between blocks, a fixation cross (FC) was presented for 2400
ms. Each block started with a presentation of the instruction cue (IC) for 2000 ms, followed by
12 trials of single digits. Stimulus presentation (SP) was 400 ms, inter-stimulus interval (ISI) 1400 ms.
Total duration of one block was 26,000 ms.
At the start of the task and in between blocks, a fixation cross was presented for 2400 ms.
Each block started with the presentation of an instruction cue (IC) for 2000 ms, followed by 12 trials
of single digits. During the trials the IC was constantly displayed on the screen. Each digit was
presented for 400 ms and followed by an inter-stimulus interval (ISI) of 1400 ms. Total duration
of one block was 26,000 ms. Blocks were presented in a mirrored design. Each block contained a
pseudorandom sequence with either two or three targets, or no more than two consecutive targets,
making a total of 20 targets within each condition. A different sequence was used for each test session.
The total task duration was 14 min. Participants pressed the left mouse button using the right-index
finger for targets. During the test visit, the task was practiced once more with and without feedback,
right after consuming the study product. The actual N-back task was performed 90 min after tyrosine
consumption, the moment that we expected the tyrosine levels to begin peaking, as based on previous
studies [2,32]. The task was presented on a laptop using Presentation 17.1 software (Neurobehavioural
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Systems, Inc., San Francisco, CA, USA). A standard protocol was used, and all tests were performed in
the same quiet room.
2.6. Plasma Tyrosine Concentrations
Plasma tyrosine concentrations were assessed at seven time points, i.e., before tyrosine
consumption (T0), and 90, 120, 150, 180, 210, and 240 min after tyrosine consumption. A peripheral
venous catheter was used to collect the blood samples into 10 mL ethylenediaminetetraacetic acid
(EDTA) vacutainers. The catheter was flushed with a solution of 0.9% of NaCl to keep it open. Directly
after collection, blood samples were centrifuged during 10 min at 1200× g and a temperature of 4 ◦C,
and plasma was transferred to 1 mL microvial tubes and stored at −80 ◦C until laboratory analyses.
Plasma tyrosine concentrations were quantified by hydrophilic interaction liquid chromatography
(HILIC) coupled with tandem mass-spectrometry as described by Prinsen and colleagues [33].
2.7. Other Measurements
We obtained information on educational level by questionnaire and education was categorized
according to Statistics Netherlands (CBS). Body height was measured at baseline with a wall-mounted
stadiometer to the nearest 0.1 cm. Body weight was measured to the nearest 0.1 kg with a calibrated
digital scale at the screening visit, with participants dressed in underwear. There was a maximum of
four weeks between the screening visit and the first test session and we instructed participants not to
change their diet, activity pattern and lifestyle during the study, so that the weight measured during
the screening visit was a reliable measure of someone’s weight at the test session. At the start of each
test session adherence to this instruction was checked with the participant.
2.8. Statistical Analysis
Data analyses were performed using IBM SPSS Statistics 22.0. Differences between older
and young adults on demographic values (age, sex, education, estimated verbal IQ, body weight,
BMI, MMSE) were determined using two-sample t-tests or chi-square tests. Plasma tyrosine
concentrations following tyrosine administration are visualized over time using mean and standard
error of the mean (SEM) per dose and age group. Outliers were determined based on Grubbs
test [34]. Baseline differences in plasma tyrosine concentrations between young and older adults
were determined using a one-way Analysis of Variance (ANOVA) on tyrosine levels after 150 mg/kg
body weight at T0, with age group (young, older adults) as the grouping variable. Baseline differences
between the three dosages within the older adult group were assessed using repeated measures (RM)
ANOVA with factor Dose (T0 tyrosine levels at baseline for doses 100, 150 mg/kg, and 200 mg/kg body
weight). The effect of age on plasma tyrosine concentrations after 150 mg/kg body weight tyrosine
administration, at baseline corrected time points (values of all time points minus T0), was assessed
using RM ANOVA with within-subjects factor Time (T90minT0, T120minT0, T150minT0, T180minT0,
T210minT0, and T240minT0) and between-subjects factor Age (young, older adults). Differential effects
of the three dosages on plasma tyrosine concentrations within older adults were determined using RM
ANOVA with within-subjects factors Dose (100, 150, and 200 mg/kg) and Time (T90minT0, T120minT0,
T150minT0, T180minT0, T210minT0, and T240minT0).
Tyrosine effects on working memory (i.e., N-back) performance was only assessed for the older
adults, as their performance could be compared between three doses. We also compared N-back
performance between the two age groups at the same dose (i.e., 150 mg/kg body weight) to replicate
the well-known age-related impairments in working memory (see Introduction). Percentage hits,
misses, correct rejections and false alarms were calculated as well as reaction times (RT) for hits and
false alarms. Within-subject RM ANOVAs using factors Dose (100, 150, and 200 mg/kg body weight)
and Cognitive Load (0-back, 1-back, 2-back, and 3-back) were used to compare percentages of hits and
false alarms as well as RT of hits on the N-back task among the three tyrosine doses. Furthermore,
we tested for an effect of individual differences in dose-related plasma level increase on N-back
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performance (percentage of hits and false alarms and RTs). For this purpose, the slope of plasma level
increase as a function of dose was calculated per subject. This was done by subtracting the baseline
(T0) from the peak measurement (T90) per dose and calculating the slope as a function of the three
increasing doses, resulting in one beta value per subject. Subsequently, ANOVAs were performed
using the within-subject factors Dose (100, 150, and 200 mg/kg body weight) and Cognitive Load
(0-back, 1-back, 2-back, and 3-back) and between-subject factor Plasma level increase (median split of
slope (beta) values into low and high tyrosine-induced plasma level increase).
Upon significant results, simple effects were assessed. We considered a two-sided p-value < 0.05
as significant.
3. Results
3.1. Participants
The flowchart of participants through the study is shown in Figure 3. For data analyses of plasma
tyrosine concentrations, one young adult was excluded based on extremely high plasma tyrosine
concentrations at T90, T180, and T240 and one older adult because of extremely low plasma tyrosine
concentrations at all time points after 100 mg/kg body weight, T150, T210, and T240 after 150 mg/kg
body weight and all time points but T0 after 200 mg/kg body weight. N-back data after the 150 mg/kg
body weight dose were missing for one older adult, who was subsequently excluded from the analyses
including this dose. Therefore, N-back data analyses within the older adults including this dose are
based on 16 individuals instead of 17. For baseline characteristics of the older and young adults, see
Table 1.
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or secondary education; High, Senior vocational/academic or tertiary education; c Median (IQR); 
Abbreviations: BMI, Body Mass Index; MMSE, Mini-Mental State Examination; N.A., not applicable; 
NART, Dutch version of the National Adult Reading Test. 
Age groups were no different in sex and body weight; the latter implicates that the absolute 
tyrosine dose also did not differ between the age groups. Older adults received less education, but 
displayed a higher estimated IQ (adjusted Dutch NART score) relative to young adults. BMI was 
higher for older than for young adults, but did not interact with our plasma outcome measures when 
added as covariate in the analyses (all p-values > 0.43). Tyrosine administrations were well tolerated; 
no adverse events were reported.  
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Table 1. Characteristics at screening of 17 young and 17 older adults assigned into the study.
Young Adults (n = 17) Older Adults (n = 17) p-Value
Age (years) 21.5 ± 2.8 a (18–30) 69.6 ± 2.9 (65–74) <0.001
Sex, Male (%) 47 47 1
Education Low/Middle/High (%) 0/6/94 b 0/29/71 0.076
Body weight (kg) 68.3 ± 9.8 73.0 ± 13.2 0.25
BMI (kg/m2) 21.5 ± 1. 25.2 2.7 <0.001
MMSE score N.A. 28 (27–29)c -
Adjusted NART score 94.8 ± 4.6 103.6 ± 5.5 <0.001
a Mean ± SD (all such values); b Dutch Education system: Low, Primary education; Middle, Vocational or secondary
education; High, Senior vocational/academic or tertiary education; c Median (IQR); Abbreviations: BMI, Body Mass
Index; MMSE, Mini-Mental State Examination; N.A., not applicable; NART, Dutch version of the National Adult
Reading Test.
Nutrients 2017, 9, 1279 7 of 14
Age groups were no different in sex and body weight; the latter implicates that the absolute
tyrosine dose also did not differ between the age groups. Older adults received less education,
but displayed a higher estimated IQ (adjusted Dutch NART score) relative to young adults. BMI was
higher for older than for young adults, but did not interact with our plasma outcome measures when
added as covariate in the analyses (all p-values > 0.43). Tyrosine administrations were well tolerated;
no adverse events were reported.
3.2. Age- and Dose-Dependent Tyrosine Effects on Plasma Tyrosine
3.2.1. Age and Time Course Comparison at 150 mg/kg Body Weight Dose
At baseline, tyrosine levels were higher for older compared with young adults (main effect of
Age group: F(1,30) = 23.35, p < 0.001) (Figure 4a). When corrected for baseline differences (all time
points minus T0), older adults displayed a higher increase in plasma tyrosine concentrations than
young adults across time points (main effect of Age group F(1,30) = 55.17, p < 0.001), driven by all
baseline-corrected time points (T90minT0: F(1,30) = 53.15; T120minT0: F(1,30) = 45.51; T150minT0:
F(1,30) = 51.20; T180minT0: F(1,30) = 40.10; T210minT0: F(1,30) = 33.45; T240minT0: F(1,30) = 35.25;
all p < 0.001) (Figure 4b). Moreover, tyrosine levels followed a different time course in older compared
with young adults (Time by Age group interaction: F(5,150) = 4.11, p = 0.002). Young adults did not
show a significant decrease with time (F(1,15) = 2.02, p = 0.086), but plasma levels decreased in the
older adults group after T150 onwards (main effect of time: F(1,15) = 11.70, p < 0.001).
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3.2.2. Dose Comparisons within Older Adults
Within the older adults group, baseline tyrosine levels at T0 did not differ among dosages.
We observed a clear dose-dependent response after administration of 100, 150, or 200 mg/kg body
weight of tyrosine in the older adults (Figure 4a). Specifically, a higher dose resulted in higher
tyrosine plasma levels relative to a lower dose (main effect of Dose on baseline corrected tyrosine
levels: F(2,30) = 151.18, p < 0.001), significant between all three doses (100 vs. 150 mg/kg body weight:
F(2,30) = 48.35, p < 0.001; 100 vs. 200 mg/kg body weight: F(1,15) = 361.32, p < 0.001; 150 vs. 200 mg/kg
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body weight: F(2,30) = 121.32, p < 0.001). Moreover, the time course of plasma levels was different
between doses 200 mg/kg and 100 mg/kg and 150 mg/kg body weight (Time (6)× Dose (100, 150, 200)
interaction: F(10,150) = 3.30, p = 0.001, driven by a Time (6)× Dose (100, 200) interaction: F(5,75) = 4.80,
p = 0.001 and a Time (6) × Dose (150, 200) interaction: F(5,75) = 4.30, p = 0.002 instead of a Time
(6) × Dose (100, 150) interaction: F(5,75) < 1). After the 200 mg/kg body weight dose, plasma levels
increased further after T90 peaking at T120 compared with the 100 mg/kg body weight (Time (T90,
T120) × Dose (100, 200) interaction: F(1,15) = 9.32, p = 0.008) and compared with the 150 mg/kg
body weight (Time (T90, T120) × Dose (150, 200) interaction: F(1,15) = 9.09, p = 0.009). Furthermore,
across doses, baseline-corrected tyrosine levels changed as a function of time (main effect of Time:
F(5,75) = 13.80, p < 0.001), with plasma levels decreasing after T150 onwards (Figure 4b).
In sum, tyrosine plasma levels in older adults increased with increasing dose. The peak was
reached half an hour later after the highest compared with the lower doses: plasma levels peaked at
90 min after the 100 mg/kg and 150 mg/kg body weight dose, but at 120 min after the 200 mg/kg dose
in older adults. Following all doses, tyrosine levels decreased from 2.5 h after ingestion, not returning
to baseline levels within four hours.
3.3. Dose-Dependent Tyrosine Effects on Working Memory Performance
For accuracy scores and RTs, see Table 2. Total percentage of hits (across levels) was greater than
60%, i.e., above chance.
Table 2. Hits, misses, correct rejections, false alarms, and reaction times on the N-back task for the
different tyrosine doses per age group.
Young Adults Older Adults
150 mg/kg (n = 17) 100 mg/kg (n = 17) 150 mg/kg (n = 16) 200 mg/kg (n = 17)
Hits (%)
0-back 100 ± 0.0 a 98.2 ± 0.9 99.1 ± 0.5 99.2 ± 0.8
1-back 98.6 ± 0.6 96.7 ± 1.0 97.2 ± 0.9 94.7 ± 3.0
2-back 90.0 ± 1.7 85.9 ± 2.5 87.1 ± 2.7 85.1 ± 3.0
3-back 78.3 ± 3.1 75.2 ± 2.9 68.1 ± 3.3 66.6 ± 4.0
Misses (%)
0-back ± 0.0 1.8 ± 0.8 0.9 ± 0.5 0.8 ± 0.8
1-back 1.4 ± 0.5 3.3 ± 1.0 2.8 ± 0.9 5.7 ± 3.0
2-back 10.0 ± 1.7 14.1 ± 2.5 12.9 ± 2.7 14.9 ± 3.0
3-back 45.0 ± 21.8 24.8 ± 2.9 31.9 ± 3.3 33.4 ± 4.0
Correct rejections (%)
0-back 99.7 ± 0.1 98.8 ± 0.3 97.8 ± 1.9 97.4 ± 2.1
1-back 99.1 ± 0.2 98.1 ± 0.6 96.5 ± 2.2 97.1 ± 1.2
2-back 98.1 ± 0.3 94.8 ± 1.0 94.7 ± 1.4 95.6 ± 1.0
3-back 96.3 ± 0.8 91.8 ± 1.1 91.4 ± 1.6 90.1 ± 1.3
False alarms (%)
0-back 0.3 ± 0.1 1.2 ± 0.3 2.2 ± 1.9 2.6 ± 2.0
1-back 0.9 ± 0.2 1.9 ± 0.6 3.5 ± 2.2 2.8 ± 1.2
2-back 1.9 ± 0.3 5.2 ± 1.0 5.3 ± 1.4 4.4 ± 1.0
3-back 3.7 ± 0.8 8.2 ± 1.1 8.6 ± 1.6 9.91 ± 1.3
Reaction time target (ms)
0-back 457.6 ± 21.4 474.3 ± 24.3 481.7 ± 23.8 483.7 ± 23.9
1-back 545.0 ± 26.4 546.5 ± 26.1 549.0 ± 23.2 548.2 ± 22.7
2-back 629.8 ± 29.9 658.2 ± 32.4 645.1 ± 30.6 620.2 ± 27.8
3-back 729.3 ± 45.3 738.1 ± 32.6 706.8 ± 35.1 713.5 ± 33.4
a Values are mean ± SEM (Standard Error of the Mean).
As expected, RT slowed down, hits decreased and false alarms increased as a function of N-back
level difficulty across age groups (main effect of Cognitive load, hits: F(3,45) = 70.28, p < 0.001;
false alarms: F(3,45) = 25.58, p < 0.001; RT: F(3,45) = 72.33, p < 0.001), and older adults performed worse
on the N-back task than young adults on the same dose of tyrosine (i.e., 150 mg/kg body weight;
hits: F(3,93) = 83.83, p < 0.001; false alarms: F(3,93) = 29.82, p < 0.001; RT: F(3,93) = 57.04, p < 0.001).
Next, we assessed the effect of different doses of tyrosine on working memory performance
(i.e., percentage of hits) in older adults. We found a dose-dependent tyrosine effect on working memory
in older adults (Dose × Cognitive load (F(6,90) = 2.23, p = 0.048) (Figure 5). This dose-dependent effect
was driven by performance on the highest working memory load, i.e., on the 3-back level (main effect
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of Dose: F(2,30) = 3.38, p = 0.047). Specifically, relative to the 100 mg/kg body weight dose, 3-back
performance decreased on the 150 and 200 mg/kg dose (150 vs. 100 mg/kg: F(1,15) = 4.98, p = 0.041;
200 vs. 100 mg/kg: F(1,16) = 6.89, p = 0.018). We did not observe performance differences on the
3-back level between 150 and 200 mg/kg body weight. On the other working memory loads (i.e., 0-, 1-,
and 2-back), no main effect of dose was observed. No main effect of dose or interactions with cognitive
load were observed on percentage of false alarms or RTs.
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Load interaction (F(6,36) = 2.85, p = 0.023), not the low plasma increase group (F(6,42) = 1.78,
p = 0.123). Specifically, within the high plasma increase group, the percentage of h s decreased
with increasing cognitive load in the 200 mg/kg body weight dose compared with 100 mg/kg body
weigh (Dose × Cognitive Load interaction: (F(3,2 = 5.32, p = 0.01). Percentage of hits as a function of
cognitive load was not different between 15 and 100 or 200 mg/kg body weight doses (F(3,18) = 1.88,
p = 0.168 and F(3,18) = 1.51, p = 0.245, respectively).
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4. Discussion
To the best of our knowledge this is the first study investigating the effects of tyrosine
administration on its plasma concentrations and cognitive effects in older adults. Using a cross-over
design, our findings showed a clear dose-related increase in plasma tyrosine concentrations after
administration of 100, 150, or 200 mg/kg body weight of tyrosine. Importantly, we observed that older
adults had a higher tyrosine plasma levels than a comparison group of young participants after the
same dose of 150 mg/kg body weight tyrosine. Furthermore, this study demonstrates unfavorable
effects of higher doses (i.e., 150 and 200 mg/kg body weight) of tyrosine relative to a lower dose
(i.e., 100 mg/kg body weight) on working memory performance in older adults. This dose-dependent
decline in terms of N-back hits was especially seen in older adults with higher dose-dependent
increases in plasma tyrosine concentrations.
Baseline plasma tyrosine concentrations of the young adults were significantly lower compared
with those of the older adults, as observed previously in women [35]. Therefore, we adjusted the
dose-response analyses for baseline tyrosine levels. Our time courses for tyrosine were similar to those
in the previous studies using a 150 mg/kg body weight dose [2,32]. However, where the increase in
tyrosine levels was two- to three-fold in those studies, the increase in our study was five- to seven-fold
in both young and older adults after the same doses of tyrosine. The larger increase in our study could
be caused by the fact that previous studies have been performed with semi-quantitative and, therefore,
less precise analysis methods for plasma tyrosine concentrations. Another reason might be the type of
carrier used for oral ingestion. The previous studies mixed the tyrosine either in water [2] or apple
Nutrients 2017, 9, 1279 11 of 14
sauce [32], whereas we used banana-flavored yoghurt to ensure comfortable ingestion (see also [36]).
Yoghurt, however, contains amino acids by itself, as well as tyrosine and other large neutral amino
acids (LNAAs). However, since our tyrosine doses were multiple times higher (i.e., the amount of
tyrosine in the yoghurt was only 4% of the amount we supplied) and, thus, prevailing, we do not
expect this has affected our results in comparison with other studies. Moreover, although other LNAAs
compete for transport across the blood-brain barrier [37], we still observed clear dose-dependent
tyrosine effects on (dopamine- instead of e.g., serotonin-related) cognitive functioning, indicating a
successful intervention. Of the total amount of LNAAs provided by the yoghurt and the supplemental
dose of tyrosine, the largest amount was also tyrosine, i.e., 94.7% versus 0.9% tryptophan and 4.3%
phenylalanine in for example the 100 mg/kg body weight dose of tyrosine with 140 mL yoghurt;
the amount supplied to an average 70 kg individual. Nevertheless, future studies should also take blood
plasma concentrations of the other LNAAs into account and calculate the plasma tyrosine/competing
amino acids ratio to determine the selectivity of the intervention. Furthermore, additional assessment
of plasma tyrosine concentrations at earlier time points, e.g., after 30 and/or 60 min after tyrosine
ingestion, would be interesting to detect the exact moment where tyrosine concentrations peak in
order to determine age-related differences in absorption and metabolic response.
In addition to increased baseline tyrosine levels, we observed higher (baseline-corrected) tyrosine
plasma levels after the same dose in older versus young adults. This effect might be due to an
age-related reduced first pass effect in the liver [3], such that higher amounts of tyrosine enter the
blood stream in older adults. Moreover, age-related insulin resistance [35], or other kinetic effects [3–5]
may contribute to reduced peripheral amino acid uptake from the blood.
On a cognitive level, relative to the lowest dose, higher doses of tyrosine were accompanied by
negative effects on working memory performance in older adults in the most difficult N-back level.
This adverse effect of tyrosine was linked to the peripheral plasma tyrosine responses, as greater
dose-dependent increases in plasma tyrosine concentrations predicted greater cognitive detriments
with increasing dose. Other studies using the same 150 mg/kg body weight tyrosine dose in
young adults, which gave adverse effects versus the 100 mg/kg body weight dose in our older
adults, have shown beneficial effects of tyrosine on working memory performance (e.g., [32,38]).
The currently-observed decrements in working memory performance with increasing tyrosine doses
in older adults might be surprising in the light of previous theories suggesting against dose-dependent
effects in young adults [17,39]. However, the older adults showed markedly increased plasma
tyrosine levels compared with the same dose in young adults, and this increase was associated
with apparently paradoxical cognitive effects. This suggests that—due to peripheral changes in
the aging body—much more tyrosine has reached, and probably crossed the blood-brain barrier
in older adults. This high central precursor availability of probable peripheral origin, may have
increased central catecholamine synthesis, subsequently leading to inhibition of tyrosine hydroxylase
(TH), the enzyme that converts tyrosine to L-dopa (i.e., the final precursor of dopamine) [40].
In rats, for example, 250 mg/kg of phenylalanine, the precursor of tyrosine, increased dopamine
release, 500 mg/kg had no effect, and 1000 mg/kg reduced dopamine release, suggesting a TH
inhibitory mechanism [41]. Detrimental effects of increasing tyrosine dose may be less surprising when
considering findings of increased dopamine synthesis capacity in older adults [25,26]. We speculate
that administrating extra precursor to a system with already high dopamine synthesis capacity may
result in its inhibition. Reduction of dopamine synthesis by inhibiting TH may also occur further in
the dopamine signaling cascade, when an excess of dopamine increases dopamine D2 autoreceptor
binding [42]. The aging brain might be more sensitive to overshoots in auto-regulation, for example
due to increased inflammatory markers, such as cytokines [43], which can alter TH availability and
autoregulatory dopamine transporter expression [44].
We did not have a placebo-controlled design and, hence, cannot infer whether tyrosine actually
improved or diminished working memory performance in older adults relative to baseline. However,
with the current design and results we do show that increasing doses of tyrosine result in detrimental
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working memory performance, questioning the cognitive enhancing potential of tyrosine in healthy
aging, at least with the currently used higher doses. Future placebo-controlled designs should further
test the beneficial or unfavorable effects of tyrosine administration on cognitive functioning in older
adults, also including lower doses <100 mg/kg body weight.
5. Conclusions
In this double-blind, randomized cross-over trial, we observed a clear dose-response in plasma
tyrosine after three different doses of tyrosine in older adults. Moreover, our data demonstrated
that plasma tyrosine concentrations were markedly increased in older compared with young adults.
Importantly, a high dose-dependent plasma tyrosine response was related to decrements in working
memory performance in older adults with higher tyrosine doses. This study shows that age-related
increases in plasma tyrosine response are associated with adverse dose-dependent effects of tyrosine
administration on cognition.
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